Enhanced normal tissue doses caused by tumour shrinkage during brachytherapy.
- 1 May 1999
- journal article
- Published by Oxford University Press (OUP) in The British Journal of Radiology
- Vol. 72 (857) , 499-501
- https://doi.org/10.1259/bjr.72.857.10505017
Abstract
Published data concerning shrinkage rates of low-grade gliomas implanted with 125I seeds have been used to determine the likely influence of such shrinkage on normal tissue doses. It is demonstrated that a tumour volume shrinkage of 50% over 6 months can bring about a 30% increase in the dose delivered to tissues which shrink centripetally towards the implanted volume. The use of radionuclides with a half-life shorter than that of 125I would substantially reduce shrinkage-induced dose increments.Keywords
This publication has 4 references indexed in Scilit:
- Calculation of integrated biological response in brachytherapyInternational Journal of Radiation Oncology*Biology*Physics, 1997
- The risk of interstitial radiotherapy of low-grade gliomasRadiotherapy and Oncology, 1997
- The effect of tumour shrinkage on biologically effective dose, and possible implications for fractionated high dose rate brachytherapyRadiotherapy and Oncology, 1994
- Radiobiological assessment of permanent implants using tumour repopulation factors in the linear-quadratic modelThe British Journal of Radiology, 1989